Article
Oncology
Mazyar Shadman
Summary: Mantle cell lymphoma remains incurable despite recent treatment advances, making individualized treatment crucial for patients. Early intervention based on high-risk features and disease progression stage is essential for improved treatment outcomes.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Biochemistry & Molecular Biology
Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, Jose Antonio Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andres Jose Maria Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thieblemont
Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.
Article
Oncology
Yong-Pyo Lee, Jung Yong Hong, Sang Eun Yoon, Junhun Cho, Joon-Ho Shim, Yeonghak Bang, Won Seog Kim, Seok Jin Kim
Summary: This study retrospectively analyzed the efficacy of lenalidomide plus rituximab in patients with relapsed or refractory DLBCL. The results showed that this combination therapy may be a salvage option, especially for cases with secondary CNS involvement, but additional agents may be needed to prolong the duration of response.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Hematology
Emmanuel Bachy, Roch Houot, Pierre Feugier, Krimo Bouabdallah, Reda Bouabdallah, Emmanuelle Nicolas Virelizier, Marie Maerevoet, Christophe Fruchart, Sylvia Snauwaert, Steven Le Gouill, Jean-Pierre Marolleau, Lysiane Molina, Cecile Molucon-Chabrot, Catherine Thieblemont, Herve Tilly, Fontanet Bijou, Corinne Haioun, Eric Van den Neste, Bettina Fabiani, Michel Meignan, Guillaume Cartron, Gilles Salles, Olivier Casasnovas, Franck Morschhauser
Summary: The combination of Obinutuzumab and lenalidomide has shown promising clinical efficacy and a manageable safety profile in various types of lymphoma. This study reported the efficacy and safety results for previously untreated patients with advanced follicular lymphoma. The combination treatment resulted in a high complete response rate, overall response rate, and favorable progression-free survival and overall survival. The most common adverse event was neutropenia.
Article
Hematology
Kunal C. Potnis, Mengyang Di, Iris Isu, Lohith Gowda, Stuart E. Seropian, Francine M. Foss, Howard P. Forman, Scott F. Huntington
Summary: In March 2021, CAR T-cell therapy was approved for use in patients with relapsed or refractory (R/R) follicular lymphoma (FL). The cost-effectiveness of CAR T-cell therapy compared to standard of care therapies in FL patients is unknown.
Letter
Oncology
Nobuhiko Nakamura, Senji Kasahara, Junichi Kitagawa, Hiroshi Nakamura, Michio Sawada, Kenji Fukuno, Yuhei Shibata, Yuto Kaneda, Takeshi Hara, Nobuhiro Kanemura, Hisashi Tsurumi, Masahito Shimizu
Summary: This study aimed to evaluate the efficacy and safety of BRAC combination therapy in patients with relapsed or refractory follicular lymphoma or mantle cell lymphoma. The results showed that BRAC therapy had a good response rate but also caused significant hematological toxicity.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Article
Hematology
Philippe Armand, Ann Janssens, Giuseppe Gritti, John Radford, John Timmerman, Antonio Pinto, Santiago Mercadal Vilchez, Peter Johnson, David Cunningham, John P. Leonard, Scott J. Rodig, Patricia Martin-Regueira, Anne Sumbul, Selda Samakoglu, Hao Tang, Stephen M. Ansell
Summary: Nivolumab monotherapy showed limited activity in patients with relapsed or refractory follicular lymphoma (FL), and better understanding of the immune biology of the disease may facilitate the development of effective checkpoint-based strategies.
Article
Oncology
Pier Luigi Zinzani, Thomas Rodgers, Dario Marino, Maurizio Frezzato, Anna Maria Barbui, Claudia Castellino, Erika Meli, Nathan H. Fowler, Gilles Salles, Bruce Feinberg, Nuwan C. Kurukulasuriya, Sascha Tillmanns, Stephan Parche, Debarshi Dey, Gunter Fingerle-Rowson, Sumeet Ambarkhane, Mark Winderlich, Grzegorz S. Nowakowski
Summary: The study demonstrated the additional treatment effect achieved by combining tafasitamab with lenalidomide in patients with R/R DLBCL, showing higher overall response rate, complete response rate, and improved survival endpoints compared to lenalidomide monotherapy.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Katsuhiro Miura, Hideki Tsujimura, Yasufumi Masaki, Masaki Iino, Jun Takizawa, Yoshinobu Maeda, Kazuhiko Yamamoto, Shinobu Tamura, Akiyo Yoshida, Hideo Yagi, Isao Yoshida, Koichi Kitazume, Taro Masunari, Ilseung Choi, Yasutaka Kakinoki, Ritsuro Suzuki, Tadashi Yoshino, Shigeo Nakamura, Yoshihiro Hatta, Takashi Yoshida, Masatoshi Kanno
Summary: The study evaluated the efficacy and safety of consolidation therapy with Y-90-IT after re-induction therapy with BR in patients with previously treated FL. Among the 22 patients who received Y-90-IT consolidation, the 2-year PFS rate was 59%, and patients whose remission lasted ≥2 years had a significantly higher PFS rate. Major adverse events were hematological toxicities, but acceptable, and the estimated 2-year overall survival after consolidation was 95%.
HEMATOLOGICAL ONCOLOGY
(2021)
Article
Oncology
Issa F. Khouri, Denai R. Milton, Alison M. Gulbis, Elias J. Jabbour, Loretta Nastoupil, Celina Ledesma, Paolo Anderlini, Qaiser Bashir, May Daher, Jin S. Im, Swaminathan P. Iyer, David Marin, Rohtesh S. Mehta, Amanda L. Olson, Uday R. Popat, Muzaffar Qazilbash, Neeraj Saini, Felipe Samaniego, Gabriela Rondon, L. Jeffrey Medeiros, Richard E. Champlin
Summary: In patients with relapsed follicular lymphoma, receiving alloSCT has been shown to confer better overall survival and progression-free survival compared to autoSCT.
CLINICAL CANCER RESEARCH
(2021)
Article
Education, Scientific Disciplines
Radhika Takiar, Yasmin Karimi, Tycel J. Phillips
Summary: Follicular lymphoma is the second most common non-Hodgkin lymphoma in the US and Western Europe. The overall outcomes for FL patients have improved over the years, but there is still a group of patients who have suboptimal treatment outcomes. Several new treatments have been approved, but further research is needed to determine the optimal management for relapsed patients.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
(2022)
Article
Hematology
G. A. Amos Burke, Luciana Vinti, Edita Kabickova, Auke Beishuizen, Nurdan Tacyildiz, Anne Uyttebroeck, Hyoung Jin Kang, Flavio Luisi, Veronique Minard-Colin, Birgit Burkhardt, Monelle Tamegnon, Steven Sun, Madeliene Curtis, Sanjay Deshpande, Kerri Nottage, Angela Howes, Srimathi Srinivasan, Deepa Bhojwani, Robin Norris, Mitchell Cairo
Summary: The results of the SPARKLE trial showed that continued assessment of ibrutinib with modified rituximab or rituximab, vincristine, ifosfamide, carboplatin, idarubicin, and dexamethasone in pediatric patients with relapsed/refractory mature B-cell non-Hodgkin lymphoma (B-NHL) did not provide a significant benefit in event-free survival. The overall response rate and overall survival were slightly higher in the ibrutinib plus chemotherapy group compared to chemotherapy alone. However, all patients in both treatment arms experienced grade >= 3 treatment-emergent adverse events. Ibrutinib exposure in pediatric patients was within the target range observed in adults.
Article
Hematology
Catherine Diefenbach, Brad S. Kahl, Andrew McMillan, Javier Briones, Lalita Banerjee, Raul Cordoba, Fiona Miall, John M. Burke, Jamie Hirata, Yanwen Jiang, Joseph N. Paulson, Yi Meng Chang, Lisa Musick, Pau Abrisqueta
Summary: Obinutuzumab combined with polatuzumab vedotin or lenalidomide showed promising tolerability and activity in previous trials for relapsed or refractory follicular lymphoma. This study aimed to investigate the efficacy of the novel Pola-G-Len combination in enhancing antitumor response. The results demonstrated high complete response rates and support further investigation of Pola-G-Len in a larger patient population.
LANCET HAEMATOLOGY
(2021)
Article
Oncology
Franck Morschhauser, Nilanjan Ghosh, Izidore S. Lossos, M. Lia Palomba, Amitkumar Mehta, Olivier Casasnovas, Don Stevens, Sudhakar Katakam, Andrea Knapp, Tina Nielsen, Ron McCord, Gilles Salles
Summary: The triplet regimen obinutuzumab-atezolizumab-lenalidomide (G-atezo-len) showed effectiveness and tolerability in patients with relapsed/refractory follicular lymphoma (FL), with a 36-month progression-free survival rate of 68.4%. Adverse events were noted in all treated patients, with two fatal events reported, both unrelated to the study drug.
BLOOD CANCER JOURNAL
(2021)
Article
Hematology
Reid W. Merryman, Robert A. Redd, Arnold S. Freedman, Inhye E. Ahn, Jennifer R. Brown, Jennifer L. Crombie, Matthew S. Davids, David C. Fisher, Eric D. Jacobsen, Austin I. Kim, Ann S. LaCasce, Samuel Ng, Oreofe O. Odejide, Erin M. Parry, Iris Isufi, Justin Kline, Jonathon B. Cohen, Neha Mehta-Shah, Nancy L. Bartlett, Matthew Mei, Thomas M. Kuntz, Jacquelyn Wolff, Scott J. Rodig, Philippe Armand, Caron A. Jacobson
Summary: Targeting multiple immune receptors may overcome immune resistance and increase response rates in patients with relapsed/refractory follicular lymphoma (FL). 4-1BB agonist therapy may have a potential role in FL, and features of the tumor microenvironment and stool microbiome could be associated with treatment outcomes.
ANNALS OF HEMATOLOGY
(2023)
Article
Medicine, General & Internal
Calvin Gan, Patricia L. Robertson, Jeffrey K. C. Lai, Jeff Szer
Summary: This study assessed the reproducibility of the LiverLab tool for evaluating bone marrow fat fraction (FF) and its ability to differentiate between Gaucher disease (GD) patients and healthy subjects. The results showed excellent reproducibility of LiverLab FF measurements and the ability to differentiate between GD patients and healthy subjects. However, the lack of statistical difference between GD patients and controls may be due to the limited number of subjects, active treatment, or mild disease severity in untreated patients.
INTERNAL MEDICINE JOURNAL
(2023)
Article
Immunology
Serena De Matteis, Michele Dicataldo, Beatrice Casadei, Gianluca Storci, Noemi Laprovitera, Mario Arpinati, Enrico Maffini, Pietro Cortelli, Maria Guarino, Francesca Vaglio, Maria Naddeo, Barbara Sinigaglia, Luca Zazzeroni, Serafina Guadagnuolo, Enrica Tomassini, Salvatore Nicola Bertuccio, Daria Messelodi, Manuela Ferracin, Massimiliano Bonafe, Pier Luigi Zinzani, Francesca Bonifazi
Summary: Inflammatory complications, such as ICANS, can affect the infusion of CAR T cells in patients with R/R-BCL. This study found that a lower percentage of CD3(+)CD8(+) lymphocytes and higher levels of CRP were associated with ICANS. Additionally, ICANS patients had an increase in senescent CD8(+) T cells and M-MDSC, as well as elevated levels of EVs carrying myeloid markers and cytokines.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Maria Rescigno, Chiara Agrati, Carlo Salvarani, Diana Giannarelli, Massimo Costantini, Alberto Mantovani, Raffaella Massafra, Pier Luigi Zinzani, Aldo Morrone, Stefania Notari, Giulia Matusali, Giuseppe Lauria Pinter, Antonio Uccelli, Gennaro Ciliberto, Fausto Baldanti, Franco Locatelli, Nicola Silvestris, Valentina Sinno, Elena Turola, Maria Teresa Lupo-Stanghellini, Giovanni Apolone
Summary: This study compared the B-cell, T-cell, and neutralizing antibody response to WT and Omicron BA.2 SARS-CoV-2 virus in patients with hematological malignancies, solid tumors, and immune-rheumatological diseases after the fourth dose of mRNA COVID-19 vaccine. The T-cell response was similarly boosted by the fourth dose across different subgroups, while the antibody response was improved only in patients not receiving B-cell targeted therapies. However, a small percentage of patients did not have neutralizing antibodies to either virus variants, making them vulnerable to SARS-CoV-2 infection. The increment of neutralizing antibodies was similar towards Omicron BA.2 and WT virus after the third or fourth dose of vaccine. Additional booster doses are recommended for frail patients to enhance the development of a B-cell response against Omicron and/or to enhance the T-cell response in patients treated with anti-CD20.
FRONTIERS IN IMMUNOLOGY
(2023)
Letter
Hematology
Eva Gonzalez Barca, Laura Tomas-Roca, Anna Esteve, Marta Rodriguez, Lucia Gato, Ruth Alonso-Alonso, Alejandro Martin Garcia-Sancho, Raul Cordoba, Anna Monter-Rovira, Mariana Bastos-Oreiro, Juan Miguel Bergua Burgues, Maria Jose Sayas, Maria Cruz Viguria Alegria, Jose Javier Sanchez-Blanco, Monica Roig Pellicer, Hugo Daniel Luzardo Henriquez, Raquel de Ona, Maria Elena Cabezudo, Maria Stefania Infante, Jose Antonio Queizan Hernandez, Rebeca Sanz-Pamplona, Oscar Blanco, Ana Mozos, Fina Climent, Miguel Angel Piris
Summary: This study used the NanoString platform to analyze the correlation matrix of unsupervised co-regulated genes, which included 208 genes. Several clusters of co-regulated genes were found to be associated with inflammatory cells, Epstein-Barr virus, B-cells, cytotoxic T-cells, T-cells, and proliferation. Additionally, the genomic alterations in 62 analyzed genes were investigated using targeted sequencing and different types of mutations were identified.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Pier Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Fogliatto, A. Martin Garcia-Sancho, Beth Christian, Zafer Gulbas, Muhit Ozcan, Guilherme Fleury Perini, Herve Ghesquieres, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand
Summary: Previous analysis of the KEYNOTE-170 study showed that pembrolizumab was effective and safe in treating relapsed/refractory PMBCL patients who had disease progression after autologous stem cell transplantation or were ineligible for the procedure. The final analysis revealed that after 4 years of follow-up, pembrolizumab still demonstrated durable responses and promising trends for long-term survival, with acceptable safety.
Article
Oncology
Marianna Gentilini, Beatrice Casadei, Alice Morigi, Ginevra Lolli, Marco Ferrari, Matteo Carella, Lisa Argnani, Pier Luigi Zinzani
Summary: Endobronchial localization of Hodgkin lymphoma is rare and there have been few reports in the literature since the 1900s. This study presents the first case of a relapsed/refractory Hodgkin lymphoma patient with a critical vegetative mass at the level of the trachea, successfully treated with pembrolizumab.
Review
Oncology
Pier Luigi Zinzani, Francesca Romana Mauro, Alessandra Tedeschi, Marzia Varettoni, Francesco Zaja, Giovanni Barosi
Summary: Zanubrutinib has been approved for the treatment of various lymphoproliferative disorders, providing a significant breakthrough for patients who are resistant or relapse after recommended therapies. Due to the lack of systematic studies and comparative randomized clinical trials, the optimal use of zanubrutinib in approved indications presents challenges, especially in earlier stages of the disorders. This article presents the results of expert panel discussions aimed at identifying unmet clinical needs and proposing recommendations for the management of these needs.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Majdolen Istaiti, Dafna Frydman, Tama Dinur, Jeff Szer, Shoshana Revel-Vilk, Ari Zimran
Summary: Ambroxol hydrochloride (ABX), an oral mucolytic drug, has shown potential as a pharmacological chaperone for mutant glucocerebrosidase. This study evaluated the safety and efficacy of 600 mg ABX per day for 12 months in three groups of Type 1 Gaucher disease patients who had a suboptimal response to standard therapies. The results showed good safety and satisfactory efficacy, suggesting that ABX could be considered as an additional treatment option for patients with GD1 who do not respond well to current therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Letter
Biophysics
M. Pena, C. Montane, A. Paviglianiti, L. Hurtado, S. Gonzalez, I. Carro, C. Maluquer, E. Domingo-Domenech, E. Gonzalez-Barca, A. Sureda, A. Mussetti
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Louis Terriou, Jong Wook Lee, Cecily Forsyth, Morag Griffin, Jeff Szer, Alexander Roeth, Philippe Gustovic, Jesse Metzger, Ami S. Patel, Christopher J. Patriquin
Summary: Using data from the International PNH Registry, the study estimated the overall survival and occurrence of thromboembolic events/major adverse vascular events (TEs/MAVEs) for eculizumab-treated PNH patients compared with an untreated cohort.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Mehdi Hamadani, Morton Coleman, Ralph Boccia, Juraj Duras, Martin Hutchings, Pier Luigi Zinzani, Raul Cordoba, Mariana Bastos Oreiro, Vanessa Williams, Huiqing Liu, Michael Stouffs, Peter Langmuir, Juan-Manuel Sancho
Summary: The combination of parsaclisib with obinutuzumab and bendamustine showed promising clinical benefit in patients with relapsed or refractory follicular lymphoma, without unexpected safety events.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Oncology
Pietro Quaglino, Nicola Pimpinelli, Pier Luigi Zinzani, Marco Paulli, Stefano Pileri, Emilio Berti, Lorenzo Cerroni, Joan Guitart, Youn H. Kim, Serena Rupoli, Marco Santucci, Gabriele Simontacchi, Maarten Vermeer, Richard Hoppe, Barbara Pro, Steven H. Swerdlow, Giovanni Barosi
Summary: This article presents major unmet clinical needs in the management of primary cutaneous B-cell lymphomas (PCBCLs) and proposes recommendations and research directions to address these needs. These recommendations and research directions will help improve the diagnosis and treatment of PCBCLs.
HEMATOLOGICAL ONCOLOGY
(2023)
Letter
Oncology
Ginevra Lolli, Lisa Argnani, Guido Gini, Beatrice Casadei, Cinzia Pellegrini, Monica Tani, Vincenzo Pavone, Michele Cimminiello, Francesca Bonifazi, Pier Luigi Zinzani
HEMATOLOGICAL ONCOLOGY
(2023)
Review
Medicine, General & Internal
Ashley McEwan, Matthew Greenwood, Christopher Ward, David Ritchie, Jeff Szer, Elizabeth Gardiner, Andriana Colic, Julija Sipavicius, Yvonne Panek-Hudson, Ian Kerridge
Summary: Haematopoietic stem cell transplantation is an important treatment for various diseases, but it can cause endothelial activation and dysfunction. This can lead to rare endothelial injury syndromes such as sinusoidal obstruction syndrome, transplant-associated thrombotic microangiopathy, idiopathic pneumonia syndrome, capillary leak syndrome, engraftment syndrome, or posterior reversible encephalopathy syndrome. This review discusses the causes, classification, diagnosis, and treatment options for these disorders.
INTERNAL MEDICINE JOURNAL
(2023)